傳港府將封鎖九龍部分地區 恆指跌幅曾擴至近450點 惟美團/藥明生物逆升2%-7%再破頂
本港去年12月整體通體通縮加劇至0.7%,遠超市場預期跌幅略擴至0.3%,且已連續第六個月呈通縮;期內基本通脹率按年放緩至零增長(前值升0.3%)。累計全年整體通脹率0.3%,基本通脹率1.3%。
據《南華早報》引述消息指,港府有意在本周末起對舊樓及分間房間林立的佐敦及深水(土步)區首次實行封鎖,屬本年以來最激進措施,以控制疫情。
恆指繼昨天反覆高見30,135創廿一個月高後輕微回軟結束三連漲後,今早在低開118點或0.4%報29,809,跌幅曾擴至448點,低見29,479喘定,現造29,550,續吐377點或近1.3%,成交額1,321億元。
藍籌股普遍跌跌逾1%-2%;因遭美制裁下周二起正式被剔出MSCI明晟全球市場指數和MSCI中國全股票指數的中海油(00883.HK)更續挫5.2%,曾低見7.8元(略失50天線7.81元)。
已連吐兩天友邦(01299.HK)、國壽(02628.HK)、萬洲(00288.HK)、瑞聲(02018.HK)、阿里(09988.HK)、中石油(00857.HK)、吉利(00175.HK)、小米(01810.HK)及銀娛(00027.HK)也跌3%-4.5%。
不過,繼花旗升價至130元後,建銀國際更升藥明生物(02269.HK)目標價至140元,料純利複合增長率逾四成,該股繼昨天破頂倒跌後,今天回升7%曾高見128.2元再創紀錄高。美團(03690.HK)低開1.4%回落至369.2元獲承接,掉頭再破頂,最高見387.6元,現造383.4元,續升2.1%。重磅股騰訊(00700.HK)續升1.8%曾見699.5元,暫受制昨天盤中所創紀錄高位700元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.